secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001193125-23-164835
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023
--------------------------------------------------------------------------------

- 7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.
- Median duration of response 8.2 months; median follow-up 8.8 months; 2 patients underwent SCT and remain in remission.
- MEN1-M3271 resistance mutation detected in only 1 of 29 patients post-ziftomenib; ziftomenib active against MEN1-T349M.
- Phase 2 registration-directed study (85 patients, 62 sites) enrollment outperforming projections; combination studies initiating.
- Differentiation syndrome manageable: 15% Grade 1/2, 5% Grade 3; safety profile consistent with underlying disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/0001193125-23-164835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/d450277d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer